Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 single ascending dose escalation study of TNX-1500 in healthy volunteers

Next Previous
Trial Profile

Phase 1 single ascending dose escalation study of TNX-1500 in healthy volunteers

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TNX 1500 (Primary)
  • Indications Autoimmune disorders; Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Tonix Pharmaceuticals Inc

Most Recent Events

  • 06 Feb 2025 According to Tonix Pharmaceuticals media release, the company plans to discuss phase 1 trial results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting.Pending alignment with the FDA, a Phase 2 study of TNX-1500 in kidney transplant recipients will be pursued.
  • 06 Feb 2025 Results evaluating Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TNX-1500 presented in the Tonix Pharmaceuticals media release.
  • 05 Mar 2024 According to Tonix Pharmaceuticals Holding Corp media release, the Phase 1 trial is intended to support dosing in a planned Phase 2 trial in kidney transplant recipients.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top